View Exam | PowerPak

1. KG is patient at high-risk for HIV due to his unsafe sexual activity and intravenous drug abuse. You would like to initiate KG on preexposure prophylaxis (PrEP) with tenofovir/emtricitabine. ALL of the following are appropriate steps to take before initiating KG on PrEP, EXCEPT:

A. Testing KG for HIV to ensure his HIV-negative status B. Confirming that KG has a creatinine clearance of 60 mL/min or higher C. Counseling KG to take the medication once a week D. Screening KG for hepatitis B virus infection

2. LK is a 43-year old male with chronic kidney disease and a history of injection drug use. He was recently diagnosed with HIV infection. His CD4 cell count is 600 cells/mm³, and he has a creatinine clearance (CrCL) of 45 mL/min. When asked about his readiness to start antiretroviral therapy (ART), LK explains that he would like to start HIV therapy. Which of the following options would you recommend for LK?

A. LK should not be initiated on ART since his CrCL is less than 80 mL/min. B. LK should not be initiated on ART since his CD4 count is more than 500 cells/mm³ and should only start treatment once his CD4 count is less than 200 cells/mm³. C. His history of injection drug use is an automatic exclusion criteria for ART. D. LK should be initiated on ART and an appropriate regimen should be selected based on his chronic kidney disease.

3. Which of the following antiretroviral therapy medications and adverse events pairings is INCORRECT?

A. Efavirenz/psychiatric effects B. Tenofovir alafenamide/hypersensitivity C. Abacavir/rash D. Tenofovir disoproxil fumarate/decreased bone mineral density

4. Which of the following statements regarding adherence to HIV prevention and treatment strategies is CORRECT?

A. The gold standard in measuring adherence is by patient self-reporting. B. In clinical trials that assess the efficacy of pre-exposure prophylaxis, low adherence rates are correlated with HIV prevention failure. C. There is significant evidence that a single tablet is more beneficial in terms of adherence compared to multi-tablet daily dosing. D. There is no association between adherence and sustained HIV suppression.

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. KG is patient at high-risk for HIV due to his unsafe sexual activity and intravenous drug abuse. You would like to initiate KG on preexposure prophylaxis (PrEP) with tenofovir/emtricitabine. ALL of the following are appropriate steps to take before initiating KG on PrEP, EXCEPT:

3. Which of the following antiretroviral therapy medications and adverse events pairings is INCORRECT?

4. Which of the following statements regarding adherence to HIV prevention and treatment strategies is CORRECT?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. KG is patient at high-risk for HIV due to his unsafe sexual activity and intravenous drug abuse. You would like to initiate KG on preexposure prophylaxis (PrEP) with tenofovir/emtricitabine. ALL of the following are appropriate steps to take before initiating KG on PrEP, EXCEPT:

3. Which of the following antiretroviral therapy medications and adverse events pairings is INCORRECT?

4. Which of the following statements regarding adherence to HIV prevention and treatment strategies is CORRECT?

« Return to Activity

Customers who Purchased
this Activity also Purchased